Antivirals Against SARS-CoV2 : Relevance to the Treatment of Alzheimer's Disease
A recent study in vitro has shown that a sulphated polysaccharide, a type of fucoidan, has potent antiviral activity against SARS-Cov2. If the antiviral action were successful also for COVID-19 patients, it would be enormously valuable against not only acute disease but also long-term mental effects, which might include Alzheimer's disease (AD). In a trial of AD patients, the apparent success of treatment with a polysaccharide, GV971, was suggested to result from antiviral action against herpes simplex virus type 1 (HSV1) in brain, a pathogen strongly implicated in AD, and that sulphation of GV971, making it fucoidan-like, might increase its putative antiviral action. These data indicate that treatment of AD patients might be very effective using valacyclovir, a conventional antiviral, which inhibits viral replication, together with a fucoidan, which blocks virus entry into cells.
Errataetall: | |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
---|---|
Enthalten in: |
Journal of Alzheimer's disease : JAD - 78(2020), 3 vom: 29., Seite 905-906 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Itzhaki, Ruth F [VerfasserIn] |
---|
Links: |
---|
Themen: |
Alzheimer’s disease |
---|
Anmerkungen: |
Date Completed 08.12.2020 Date Revised 05.01.2022 published: Print CommentOn: Cell Discov. 2020 Jul 24;6:50. - PMID 32714563 Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3233/JAD-200986 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM316436461 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM316436461 | ||
003 | DE-627 | ||
005 | 20231225161058.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3233/JAD-200986 |2 doi | |
028 | 5 | 2 | |a pubmed24n1054.xml |
035 | |a (DE-627)NLM316436461 | ||
035 | |a (NLM)33074241 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Itzhaki, Ruth F |e verfasserin |4 aut | |
245 | 1 | 0 | |a Antivirals Against SARS-CoV2 |b Relevance to the Treatment of Alzheimer's Disease |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.12.2020 | ||
500 | |a Date Revised 05.01.2022 | ||
500 | |a published: Print | ||
500 | |a CommentOn: Cell Discov. 2020 Jul 24;6:50. - PMID 32714563 | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a A recent study in vitro has shown that a sulphated polysaccharide, a type of fucoidan, has potent antiviral activity against SARS-Cov2. If the antiviral action were successful also for COVID-19 patients, it would be enormously valuable against not only acute disease but also long-term mental effects, which might include Alzheimer's disease (AD). In a trial of AD patients, the apparent success of treatment with a polysaccharide, GV971, was suggested to result from antiviral action against herpes simplex virus type 1 (HSV1) in brain, a pathogen strongly implicated in AD, and that sulphation of GV971, making it fucoidan-like, might increase its putative antiviral action. These data indicate that treatment of AD patients might be very effective using valacyclovir, a conventional antiviral, which inhibits viral replication, together with a fucoidan, which blocks virus entry into cells | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Comment | |
650 | 4 | |a Alzheimer’s disease | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Herpes simplex virus type 1 | |
650 | 4 | |a SARS-Cov2 | |
650 | 4 | |a antiviral | |
650 | 4 | |a fucoidans | |
773 | 0 | 8 | |i Enthalten in |t Journal of Alzheimer's disease : JAD |d 1998 |g 78(2020), 3 vom: 29., Seite 905-906 |w (DE-627)NLM097527327 |x 1875-8908 |7 nnns |
773 | 1 | 8 | |g volume:78 |g year:2020 |g number:3 |g day:29 |g pages:905-906 |
856 | 4 | 0 | |u http://dx.doi.org/10.3233/JAD-200986 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 78 |j 2020 |e 3 |b 29 |h 905-906 |